Clinical trial
Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using…
NCT00468806 · GlaxoSmithKline, Industry · Completed
Key facts
| NCT number | NCT00468806 |
|---|---|
| Title | Study of Safety, Blood Levels and Brain Receptor Occupancy of GSK598809 Using PET Imaging in Health Males. |
| Official title | An Open Label Positron Emission Tomography Study in Healthy Male Subjects to Investigate Brain Dopamine D3 Occupancy Kinetics, Pharmacokinetics and Safety of Single Oral Doses of GSK598809, Using [11C]-(+)-PHNO as PET Ligand. |
| Lead sponsor | GlaxoSmithKline, Industry |
| Status | Completed |
| Phase | Phase 1 |
| Study type | Interventional |
| Conditions | Healthy Subjects |
| Intervention type | Drug |
| Interventions | GSK598809, using [11C]-(+)-PHNO |
| Enrollment | 25 |
| Start date | Apr 1, 2007 |
| Primary completion | May 1, 2008 |
| Completion | May 1, 2008 |
| First posted | May 3, 2007 |
| Last update posted | Oct 28, 2010 |
| Countries | Canada |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: